Eisai Co., Ltd. (ESALF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
71.510.00 (0.00%)
As of 12:19PM EST. Market open.
| Previous close | 71.51 |
| Open | 71.51 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 71.51 - 71.51 |
| 52-week range | 22.00 - 90.35 |
| Volume | 29 |
| Avg. volume | 1,220 |
| Market cap | 19.123B |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | 23.65 |
| EPS (TTM) | 3.02 |
| Earnings date | N/A |
| Forward dividend & yield | 1.45 (2.03%) |
| Ex-dividend date | 30 Mar 2021 |
| 1y target est | N/A |
- Zacks
Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study
Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.
- Zacks
Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins
A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.
- Zacks
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.
© 2021 Verizon Media. All rights reserved.
